156 related articles for article (PubMed ID: 37524106)
21. Ribociclib plus letrozole in early breast cancer: A presurgical, window-of-opportunity study.
Curigliano G; Gómez Pardo P; Meric-Bernstam F; Conte P; Lolkema MP; Beck JT; Bardia A; Martínez García M; Penault-Llorca F; Dhuria S; Tang Z; Solovieff N; Miller M; Di Tomaso E; Hurvitz SA
Breast; 2016 Aug; 28():191-8. PubMed ID: 27336726
[TBL] [Abstract][Full Text] [Related]
22. Comparison of treatment-related adverse events of different Cyclin-dependent kinase 4/6 inhibitors in metastatic breast cancer: A network meta-analysis.
Desnoyers A; Nadler MB; Kumar V; Saleh R; Amir E
Cancer Treat Rev; 2020 Nov; 90():102086. PubMed ID: 32861975
[TBL] [Abstract][Full Text] [Related]
23. Ribociclib-induced liver injury: a case report.
Schaeffer S; Lutz C; Dobbie M; Terracciano LM; Matter M; Vosbeck J; Heim MH; Bernsmeier C
Front Oncol; 2023; 13():1256783. PubMed ID: 38107071
[TBL] [Abstract][Full Text] [Related]
24. Ribociclib plus fulvestrant in the treatment of breast cancer.
Neven P; Sonke GS; Jerusalem G
Expert Rev Anticancer Ther; 2021 Jan; 21(1):93-106. PubMed ID: 33085548
[TBL] [Abstract][Full Text] [Related]
25. Cyclin-dependent kinase 4/6 inhibitors in breast cancer: palbociclib, ribociclib, and abemaciclib.
Kwapisz D
Breast Cancer Res Treat; 2017 Nov; 166(1):41-54. PubMed ID: 28741274
[TBL] [Abstract][Full Text] [Related]
26. Ribociclib in newly diagnosed hepatitis B infection: A case report.
Di Costanzo F; Carrano S; Iengo G; Cefaliello A; Cossiga V; Morisco F; Giuliano M; De Angelis C; Arpino G
Front Oncol; 2023; 13():1184952. PubMed ID: 37361578
[TBL] [Abstract][Full Text] [Related]
27. Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial.
Tripathy D; Im SA; Colleoni M; Franke F; Bardia A; Harbeck N; Hurvitz SA; Chow L; Sohn J; Lee KS; Campos-Gomez S; Villanueva Vazquez R; Jung KH; Babu KG; Wheatley-Price P; De Laurentiis M; Im YH; Kuemmel S; El-Saghir N; Liu MC; Carlson G; Hughes G; Diaz-Padilla I; Germa C; Hirawat S; Lu YS
Lancet Oncol; 2018 Jul; 19(7):904-915. PubMed ID: 29804902
[TBL] [Abstract][Full Text] [Related]
28. Rationale and trial design of NATALEE: a Phase III trial of adjuvant ribociclib + endocrine therapy
Slamon DJ; Fasching PA; Hurvitz S; Chia S; Crown J; Martín M; Barrios CH; Bardia A; Im SA; Yardley DA; Untch M; Huang CS; Stroyakovskiy D; Xu B; Moroose RL; Loi S; Visco F; Bee-Munteanu V; Afenjar K; Fresco R; Taran T; Chakravartty A; Zarate JP; Lteif A; Hortobagyi GN
Ther Adv Med Oncol; 2023; 15():17588359231178125. PubMed ID: 37275963
[TBL] [Abstract][Full Text] [Related]
29. Ribociclib Plus Trastuzumab in Advanced HER2-Positive Breast Cancer: Results of a Phase 1b/2 Trial.
Goel S; Pernas S; Tan-Wasielewski Z; Barry WT; Bardia A; Rees R; Andrews C; Tahara RK; Trippa L; Mayer EL; Winer EP; Spring LM; Tolaney SM
Clin Breast Cancer; 2019 Dec; 19(6):399-404. PubMed ID: 31235441
[TBL] [Abstract][Full Text] [Related]
30. Ribociclib plus letrozole versus chemotherapy for postmenopausal women with hormone receptor-positive, HER2-negative, luminal B breast cancer (CORALLEEN): an open-label, multicentre, randomised, phase 2 trial.
Prat A; Saura C; Pascual T; Hernando C; Muñoz M; Paré L; González Farré B; Fernández PL; Galván P; Chic N; González Farré X; Oliveira M; Gil-Gil M; Arumi M; Ferrer N; Montaño A; Izarzugaza Y; Llombart-Cussac A; Bratos R; González Santiago S; Martínez E; Hoyos S; Rojas B; Virizuela JA; Ortega V; López R; Céliz P; Ciruelos E; Villagrasa P; Gavilá J
Lancet Oncol; 2020 Jan; 21(1):33-43. PubMed ID: 31838010
[TBL] [Abstract][Full Text] [Related]
31. Ribociclib-induced hepatotoxicity.
Er MM; Araz M; Hendem E; Eryılmaz MK; Artaç M
J Oncol Pharm Pract; 2023 Jul; 29(5):1275-1277. PubMed ID: 36762416
[TBL] [Abstract][Full Text] [Related]
32. Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer.
Hortobagyi GN; Stemmer SM; Burris HA; Yap YS; Sonke GS; Paluch-Shimon S; Campone M; Blackwell KL; André F; Winer EP; Janni W; Verma S; Conte P; Arteaga CL; Cameron DA; Petrakova K; Hart LL; Villanueva C; Chan A; Jakobsen E; Nusch A; Burdaeva O; Grischke EM; Alba E; Wist E; Marschner N; Favret AM; Yardley D; Bachelot T; Tseng LM; Blau S; Xuan F; Souami F; Miller M; Germa C; Hirawat S; O'Shaughnessy J
N Engl J Med; 2016 Nov; 375(18):1738-1748. PubMed ID: 27717303
[TBL] [Abstract][Full Text] [Related]
33. Randomized Phase II Trial of Endocrine Therapy With or Without Ribociclib After Progression on Cyclin-Dependent Kinase 4/6 Inhibition in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: MAINTAIN Trial.
Kalinsky K; Accordino MK; Chiuzan C; Mundi PS; Sakach E; Sathe C; Ahn H; Trivedi MS; Novik Y; Tiersten A; Raptis G; Baer LN; Oh SY; Zelnak AB; Wisinski KB; Andreopoulou E; Gradishar WJ; Stringer-Reasor E; Reid SA; O'Dea A; O'Regan R; Crew KD; Hershman DL
J Clin Oncol; 2023 Aug; 41(24):4004-4013. PubMed ID: 37207300
[TBL] [Abstract][Full Text] [Related]
34. Complete Clinical Response in Locally Advanced Metastatic de novo Breast Cancer after Front-Line Treatment with Ribociclib/Letrozole within the RIBANNA Study.
Rudlowski C; Beermann N; Leitzen L; Nuding B
Breast Care (Basel); 2020 Jun; 15(3):289-293. PubMed ID: 32774224
[TBL] [Abstract][Full Text] [Related]
35. Phase I/II Trial of Exemestane, Ribociclib, and Everolimus in Women with HR
Bardia A; Hurvitz SA; DeMichele A; Clark AS; Zelnak A; Yardley DA; Karuturi M; Sanft T; Blau S; Hart L; Ma C; Rugo HS; Purkayastha D; Moulder S
Clin Cancer Res; 2021 Aug; 27(15):4177-4185. PubMed ID: 33722897
[TBL] [Abstract][Full Text] [Related]
36. Intrinsic subtypes and therapeutic decision-making in hormone receptor-positive/HER2-negative metastatic breast cancer with visceral crisis: A case report.
Schettini F; Seguí E; Conte B; Sanfeliu E; Gonzalez-Farre B; Jares P; Vidal-Sicart S; Ganau S; Cebrecos I; Brasó-Maristany F; Muñoz M; Prat A; Vidal M
Front Oncol; 2022; 12():1009352. PubMed ID: 36425558
[TBL] [Abstract][Full Text] [Related]
37. Elevated transaminases and development of cardiomyopathy in a 32-year-old woman with metastatic breast cancer after treatment with ribociclib followed by palbociclib.
Watts C; Nadori K
J Oncol Pharm Pract; 2023 Jun; 29(4):962-966. PubMed ID: 36000297
[TBL] [Abstract][Full Text] [Related]
38. Ribociclib in the Treatment of Hormone-Receptor Positive/HER2-Negative Advanced and Early Breast Cancer: Overview of Clinical Data and Patients Selection.
Parati MC; Pedersini R; Perego G; Reduzzi R; Savio T; Cabiddu M; Borgonovo K; Ghilardi M; Luciani A; Petrelli F
Breast Cancer (Dove Med Press); 2022; 14():101-111. PubMed ID: 35440873
[TBL] [Abstract][Full Text] [Related]
39. Case Report of Probable DRESS Syndrome Associated with Ribociclib.
Carneiro F; Bove M; Beau-Salinas F; San T; Combe P
Case Rep Oncol Med; 2023; 2023():7904950. PubMed ID: 38046373
[TBL] [Abstract][Full Text] [Related]
40. Cost Effectiveness of Ribociclib and Palbociclib in the Second-Line Treatment of Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer in Post-Menopausal Indian Women.
Gupta N; Gupta D; Dixit J; Mehra N; Singh A; Krishnamurthy MN; Jyani G; Rajsekhar K; Kalaiyarasi JP; Roy PS; Malik PS; Mathew A; Malhotra P; Gupta S; Kumar L; Kataki A; Prinja S
Appl Health Econ Health Policy; 2022 Jul; 20(4):609-621. PubMed ID: 35534752
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
